Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Landgren O, Kyle RA, Rajkumar SV.

Clin Cancer Res. 2011 Mar 15;17(6):1243-52. doi: 10.1158/1078-0432.CCR-10-1822. Review.

PMID:
21411440
[PubMed - indexed for MEDLINE]
Free Article
2.

Development of early treatment strategies for high-risk myeloma precursor disease in the future.

Landgren O, Rajkumar SV.

Semin Hematol. 2011 Jan;48(1):66-72. doi: 10.1053/j.seminhematol.2010.11.009. Review.

PMID:
21232660
[PubMed - indexed for MEDLINE]
3.

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.

Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.

Leuk Lymphoma. 2010 Dec;51(12):2159-70. doi: 10.3109/10428194.2010.525725. Epub 2010 Oct 20. Review.

PMID:
20958231
[PubMed - indexed for MEDLINE]
4.

Multiple myeloma precursor disease.

Landgren O, Waxman AJ.

JAMA. 2010 Dec 1;304(21):2397-404. doi: 10.1001/jama.2010.1713.

PMID:
21119086
[PubMed - indexed for MEDLINE]
5.

Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.

Hillengass J, Moehler T, Hundemer M.

Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Review.

PMID:
21509683
[PubMed - indexed for MEDLINE]
6.

Molecular imaging in myeloma precursor disease.

Mena E, Choyke P, Tan E, Landgren O, Kurdziel K.

Semin Hematol. 2011 Jan;48(1):22-31. doi: 10.1053/j.seminhematol.2010.11.006. Review.

PMID:
21232655
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Landgren O.

Hematology Am Soc Hematol Educ Program. 2010;2010:295-302. doi: 10.1182/asheducation-2010.1.295. Review.

PMID:
21239809
[PubMed - indexed for MEDLINE]
Free Article
8.

Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.

Klincová M, Sandecká V, Mikuláiová A, Radocha J, Maisnar V, Hájek R.

Klin Onkol. 2011;24 Suppl:S14-7. Review.

PMID:
21923058
[PubMed - indexed for MEDLINE]
9.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Korde N, Kristinsson SY, Landgren O.

Blood. 2011 May 26;117(21):5573-81. doi: 10.1182/blood-2011-01-270140. Epub 2011 Mar 25. Review.

PMID:
21441462
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group.

Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Review.

PMID:
20410922
[PubMed - indexed for MEDLINE]
11.

Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.

Kristinsson SY, Björkholm M, Schulman S, Landgren O.

Semin Hematol. 2011 Jan;48(1):46-54. doi: 10.1053/j.seminhematol.2010.11.002. Review.

PMID:
21232658
[PubMed - indexed for MEDLINE]
12.

Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.

Bladé J, Rosiñol L.

Curr Treat Options Oncol. 2006 May;7(3):237-45. Review.

PMID:
16615879
[PubMed - indexed for MEDLINE]
13.

Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Minter AR, Simpson H, Weiss BM, Landgren O.

Semin Hematol. 2011 Jan;48(1):55-65. doi: 10.1053/j.seminhematol.2010.11.001. Review.

PMID:
21232659
[PubMed - indexed for MEDLINE]
14.

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E.

J Clin Oncol. 2002 Mar 15;20(6):1625-34.

PMID:
11896113
[PubMed - indexed for MEDLINE]
Free Article
15.

Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.

Kyle RA, Rajkumar SV.

Br J Haematol. 2007 Dec;139(5):730-43. Review.

PMID:
18021088
[PubMed - indexed for MEDLINE]
16.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Agarwal A, Ghobrial IM.

Clin Cancer Res. 2013 Mar 1;19(5):985-94. doi: 10.1158/1078-0432.CCR-12-2922. Epub 2012 Dec 5. Review.

PMID:
23224402
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):248-57. doi: 10.3816/CLML.2010.n.053. Review.

PMID:
20709660
[PubMed - indexed for MEDLINE]
18.

Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O.

Expert Rev Mol Diagn. 2011 Jul;11(6):593-603. doi: 10.1586/erm.11.44. Review.

PMID:
21745013
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

Berenson JR, Yellin O.

Clin Lymphoma Myeloma. 2009 Aug;9(4):311-5. doi: 10.3816/CLM.2009.n.061.

PMID:
19717382
[PubMed - indexed for MEDLINE]
20.

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV.

Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332.

PMID:
20472173
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk